Faculty: Romina Mizrahi, MD, PhD

Romina Mizrahi, MD, PhDRomina Mizrahi, MD, PhD
Associate Professor, Department of Psychiatry
Clinician Scientist, Schizophrenia program, PET Centre, CAMH

General Research Areas: Clinical Pharmacology; Neuropharmacology; Psychopharmacology
Imaging Brain Chemistry in Psychosis and Patients at Clinical High Risk for Psychosis

My goal is to develop a better understanding of how the brain functions in-vivo. Specifically, my focus is the pathophysiology of the early course of schizophrenia and its treatment. In pursuit of this goal I use phenomenology and positron emission tomography (PET).

Selected Publications:

Hafizi S, Tseng H, Rao N, Selvanathan T, Kenk M, Bazinet RP, Suridjan I, Wilson A, Meyer JH, Remington G, Houle S, Rusjan PM, Mizrahi R. Imaging Microglial activation in untreated first-episode psychosis: A PET study with [18F]FEPPA. American Journal of Psychiatry. 2017 Feb; 174(2):118-124.

Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, Pruessner JC, Remington G, Houle S, Wilson AA. Increased stress-induced dopamine release in psychosis. Biol Psychiatry. 2012; 71(6):561-7.

Mizrahi R. Advances in PET analyses of stress and dopamine. Hot Topics Special Edition. Invited review for Neuropsychopharmacology. 2010 Jan; 35(1):348-9.

Mizrahi R, Rusjan P, Agid O, Graff, Mamo D,  Zipursky  RB, Kapur S. Subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors -  PET study in first episode schizophrenia. American Journal of Psychiatry. 2007 Apr; 164(4):630-7

Barron H, Hafizi S, Andreazza AC, Mizrahi R. Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk. International Journal of Molecular Science. 2017. 18(3).

Mizrahi R. Social stress and psychosis risk: common neurochemical substrates? Neuropsychopharmacology. 2016 Feb. 41(3):666-74. Review

Kenk M, Selvanathan T, Suridjan I, Rusjan P, Rao N, Remington G, Meyer J, Wilson A, Houle S, Mizrahi R. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophrenia Bulletin. 2015 Jan. 41(1):85-93

Suridjan I, Rusjan PM, Kenk M, Verhoeff NP, Voineskos AN, Rotenberg D, Wilson AA, Meyer JH, Houle S, Mizrahi R. Quantitative imaging of neuroinflammation in human white matter: a Positron Emission Tomography (PET) study with Translocator protein 18kDA (TSPO) radioligand, [18F]-FEPPA. Synapse 2014 Nov. 68(11):536-47

Mizrahi R, Kenk M, Suridjan I, Boileau I, George TP, McKenzie K, Wilson AA, Houle S, Rusjan P. Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology. 2014 Feb. 39(6):1479-89

Mizrahi R, Suridjan I, Kenk M, George TP, Wilson AA, Houle S, Rusjan PM. Dopamine response to psychosocial stress in chronic cannabis users: A PET study with [11C]-(+)-PHNO. Neuropsychopharmacology. 2013 Mar. 38(4):673-82

Mizrahi R, Rusjan P, Kennedy JL, Pollock B, Muslant B, Suridjdan I, Deluca V, Wilson AA, and  Houle S. Translocator Protein (18 kDa) polymorphism (rs 6971) explains in-vivo brain binding affinity of the PET radioligand [18F]-FEPPA. Journal of Cerebral Blood Flow & Metabolism. 2012 Jun. 32(6):968-72. PA

Mizrahi R, Rusjan P, Vitcu I, Ng A, Wilson AA, Houle S, Bloomfield PM. Whole-body distribution and radiation dosimetry of [11C]-(+)-PHNO, a D2/3 agonist ligand. Journal of Nuclear Medicine Nov. 2012; 53(11): 1802-6.

Contact:

Centre for Addiction and Mental Health – CAMH 
250 College Street
Toronto, ON, M5T 1R8 
Telephone: (416) 535-8501 Ext. 34508 
Fax (416) 260-4164 
Email: romina.mizrahi@camhpet.ca or romina_mizrahi@camh.ca 

Back to Top